WWHS Biotech.Inc(exclusive marketed by Dawin)
Revolutionary NIR technology, Ultra-high Sensitivity and Higher Performance in POCT
Add to Cart
High Precision CK19 Rapid Test Kit IVD Cytokeratin 19 Fragment Tumor Marker Clinical Diagnosis
Intended use
Tumor Maker
Characteristics
1. Accurate: Double antibody sandwich method, high sensitivity.
2. Rapid: Get results in 15 minutes.
3. Convenient: No need professional training, test could be performed at any time, any place.
Our Services
1. Provide LOGO, color, outlook and GUI customization.
2. Provide technical support and training.
3. Provide training video.
Sales Service:
1. Professional service of the whole exporting processing .
2. Give supporting on your sales chennel establishment of our products.
3. OEM accepted.
After Services:
1.Guarantee for 1 year
2.Quik answer and solution for any problem during your operation
About NIR-1000 Dry Fluoroimmunoassay Analyser
It is a fluorescence immunochromatographic analysing system with internal temperature control, which can help diagnose conditions such as infection, diabetes, cardiovascular diseases, renal injury and cancers, etc.
* Immunofluorescence technology
* Testing time less than 15 minutes
* Easy-to-use touch-screen platform,multi-language system
* Reagents stored at room temperature for 12 months
* Dry immune technology, maintenance free
| Tumor Marker | ||||||
| cat#. | Product Item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
| 20 | AFP | Serum/Plasma | 15min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
| 21 | CEA | Serum/Plasma | 15min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
| 22 | NSE | Serum/Plasma | 15min. | 1-400ng/ml | <16ng/ml | non-small cell lung cancer |
| 23 | FOB | fecal specimens | 10min. | 50-1000ng/ml | <100ng/ml | Abnormal recessive gastrointestinal bleeding |
| 24 | PG II | Serum/Plasma | 15min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
| 25 | PG I | Serum/Plasma | 15min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
| 26 | TPSA | Serum/Plasma | 15min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
| 27 | FPSA | Serum/Plasma | 15min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
| 28 | CA12-5 | Serum/Plasma | 15min. | 20-500U/ml | <35U/ml | ovarian cancer |
| 29 | CA15-3 | Serum/Plasma | 15min. | 10-400U/ml | < 25 U/mL | breast cancer |
| 30 | HE4 | Serum/Plasma | 15min. | 50-2000pmol/L | <140 pmol/L | ovarian cancer |
| 31 | CA19-9 | Serum/Plasma | 15min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
| 32 | β-HCG | Serum/Plasma | 15min. | 5-400mIU/ml | <10 mIU/mL | Early pregrancy, ectopic HCG cancer,incomplete abortion |
| 33 | CK19(Cyfra21-1) | Serum/Plasma | 15min. | 0.5-50ng/ml | <2.5ng/ml | non-small cell lung cancer |
Applicable Instrument
WWHS NIR-1000 dry fluoroimmunoassay analyser